SHORT COURSES
Saturday, May 18, 8:00 a.m. - 5:00 p.m.
Bayesian Analysis - Overview and Applications
Faculty: Christopher Hollenbeak, PhD, Assoc. Prof., Surgery and Public Health Sciences, Penn State College of Medicine; David Vanness, PhD, Asst. Prof., Univ. of Wisconsin, and Visiting Scientist, Health Economics and Science Policy, UBC

Sunday, May 19, 8:00 a.m. - 12 p.m.
Discrete Event Simulation for Economic Analyses - Concepts
Faculty: J. Jaime Caro, MDCM, FRCPC, FACP, Adjunct Prof. of Medicine, Adjunct Prof. Epidemiology & Biostatistics, McGill Univ., Canada, and Sr. VP Health Economics, UBC; Jörgen Möller, MSc Mech Eng, VP Modeling, UBC, Assoc. Researcher, Div. of Health Economics, Lund Univ., Sweden; Denis Getsios, Sr. Dir., Sr. Research Scientist, UBC

Sunday, May 19, 1:00 p.m. - 5:00 p.m.
Discrete Event Simulation for Economic Analyses - Applications
Faculty: J. Jaime Caro, MDCM, FRCPC, FACP, Adjunct Prof. of Medicine, Adjunct Prof. Epidemiology & Biostatistics, McGill Univ., Canada, and Sr. VP Health Economics, UBC; Jörgen Möller, MSc Mech Eng, VP Modeling, UBC, Assoc. Researcher, Div. of Health Economics, Lund Univ., Sweden; Denis Getsios, Sr. Dir., Sr. Research Scientist, UBC

PLENARY SESSION
Wednesday, May 22, 9:45 a.m. - 11:00 a.m.
SESSION TOPIC: Assessing the Evidence for the Health Care Decision Maker
Assessing Modeling Studies for Health Care Decisions
UBC Speaker: J. Jaime Caro, MDCM, FRCPC, FACP, Sr. VP Health Economics, UBC

ISPOR FORUM
SESSION II - Tuesday, May 21, 6:15 p.m. - 7:15 p.m.
Using Mixed Modes to Capture Patient-Reported Outcomes Data in Clinical Trials
Moderator & Speaker: Sonya Eremenco, MA, Chair, ISPOR PRO Task Force: Good Research Practices for Mixed Modes to Collect PRO Data in Clinical Trials, and Dir. ePRO New Products, UBC
Speakers: Stephen Joel Coons, PhD, MEd, MSc, Med, Dir., Patient-Reported Outcomes Consortium, Critical Path Inst.; Jean Paty, PhD, Chief Scientist and Regulatory Advisor - Outcomes, ERT, Inc.

SESSION III - Tuesday, May 21, 5:00 p.m. - 6:00 p.m.
W19: The Utility of Mixed-Method Approaches to Evaluate the Content Validity of PRO Measures
Discussion Leaders: William R. Lenderking, PhD, Sr. Research Leader, UBC; Cheryl Coon, PhD, Dir., Psychometrics, RTI Health Solutions; Sheri E. Fehnel, PhD, VP, Patient-Reported Outcomes, RTI Health Solutions; Laurie B. Burke, RPh, MPH, Dir., Study Endpoints and Label Development, CDER, U.S. FDA

ISSUE PANEL
SESSION II - Tuesday, May 21, 11:00 a.m. - 12:00 p.m.
IP8: Can Bayesian Adaptive CER Trial Designs Bridge the Needs of Patients, Payers, Regulators and Manufacturers
Moderator: Jack Ishak, PhD, Dir. and Sr. Research Scientist, Biostatistics and Epidemiology, UBC
Panelists: Rachael Fleurence, PhD, Dir., Patient-Centered Outcomes Research Inst. (PCORI); Charles E. Barr, MD, MPH, Medical Dir., Head of Registries, Medical Affairs, Genentech; Robert T. O’Neill, PhD, Dir. Office of Biostatistics, CDER, U.S. FDA (Invited)

WORKSHOPS
SESSION I - Monday, May 20, 5:00 p.m. - 6:00 p.m.
W4: Capturing Patient and Observer Perspectives for Evaluating Treatments for Pediatric Mental Health Conditions - Opportunities and Challenges
Discussion Leaders: Asha Hareendran, PhD, MA, Sr. Research Scientist, UBC; Juliana Setyawati, PharmD, MS, PhD, Shire Development; Keith Saylor, PhD, Licensed Clinical Psychologist, NeuroScience Inc.; Elektra Papdopoulos, MD, MPH, CDER, U.S. FDA

W6: Best Practices and Promising Models for Patient Engagement in Patient-Centered Research
Discussion Leaders: Kathleen W. Wyrwich, PhD, Sr. Research Leader, UBC; Sue Sheridan, MIM, MBA, Dir. of Patient Engagement, Patient-Centered Outcomes Research Inst.; Theresa Mullin, PhD, Dir., Office of Planning and Informatics, CDER, U.S. FDA; Steven I. Blum, MBA, Dir., Health Economics and Outcomes Research, Forest Research Inst.
SESSION IV - Wednesday, May 22, 1:45 p.m. - 2:45 p.m.

**W24: Novel Approaches in Early Planning for Relevant Evidence Generation to Support Health Care Decision Making**

**Discussion Leaders:** L. Clark Paramore, MSPH, Sr. Research Scientist, Health Economics, UBC; Rob Thwaites, MA, VP, Health Economics, UBC; Floortje E. van Nooten, MSc, Assoc. Dir., HEOR, Astellas; Jan E. Hansen, PhD, DPH, VP, Global Health Outcomes, Allergan

SESSION V - Wednesday, May 22, 3:00 p.m. - 4:00 p.m.

**W27: Evaluations of Treatment Pathways in Oncology: Clinical and Economic Considerations and Modeling Approaches**

**Discussion Leaders:** Sonja Sorensen, MPH, Sr. Research Scientist, UBC; Feng Pan, PhD, Research Scientist, UBC; Jianming He, MS, MA, Assoc. Dir., Janssen Global Services; Kevin Knopf, MD, MPH, Medical Oncologist, California Pacific Medical Center

**W28: Adapting AMCP Format-Based Dossiers: Evidence Guidelines for Specialty Pharmaceuticals. Companion Diagnostics, and Comparative Effectiveness Research**

**Discussion Leaders:** Jeff Lee, PharmD, National Dir., Regional Scientific Services, Allergan; Bryan R. Luce, PhD, MBA, Sr. VP, Science Policy, UBC; Pete Penna, PharmD, President, Formulary Resources; David L. Veenstra, PhD, PharmD, Prof., Dept. of Pharmacy, Pharmaceutical Outcomes Research and Policy Program, Univ. of Washington

**W31: The Use of Patient-Centered Health Care Information from Social Networking Sources in Health Economics and Outcomes Research**

**Discussion Leaders:** Luke Boulanger, MA, MBA, Sr. Research Scientist and Sr. Dir., Health Economics, UBC, Doug McClure, MIM, Chief Technology Officer, Healthrageous; L. Clark Paramore, MSPH, Sr. Research Scientist, Health Economics, UBC

PODIUM PRESENTATIONS

**SESSION I - Monday, May 20, 2:15 p.m. - 3:15 p.m.**

**CP3:** Piecewise Modeling of Time-to-Event Data with Flexible Parameterization of Covariates and Effects

Ishak J

**SESSION II - Monday, May 20, 3:45 p.m. - 4:45 p.m.**

**CE3:** Advantages of Bayesian Adaptive Trials for Comparative Effectiveness Research (CER): “Re-Adap’ting ALLHAT”

Broglia K, Ishak J, Mullins CD, Connor J, Luce BR, Davis B

POSTER PRESENTATIONS

**SESSION I - Monday, May 20, 8:30 a.m. - 2:15 p.m.**

**PMHS3:** Development of a Conceptual Disease Model to Inform Strategy to Evaluate Treatment Impact in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)


**PRM66:** Use of Common Data Model to Meaningfully Compare Treatment Patterns for Depression among Disparate Databases

Reisinger S, Powell G, Dreyfus B, Schneider G

**PRM74:** Modeling the Economic Implications of Alternative Treatments and Care Locations for Acute Bacterial Skin and Skin Structure Infections: Results from a Discrete Event Simulation


**PRM120:** Development of a New Patient-Reported Outcome (PRO) Instrument for Pulmonary Arterial Hypertension (PAH): The Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire

McCollister D, Kummer S, Badesch DB, Filushe A, Hunsche E, Schuler R, Wiklund I, Peacock A

**PRM144:** An Adaptable Methodology for the Design, Implementation and Conduct of a Web-Based Survey Assessing Burden of Illness and Racial Differences: Case Study of Adult Females with Acne

Yeomans K, Kawata AK, Bassel M, Burk CT, Daniels SR, Wilcox TK

**PRM206:** Methodological Challenges in the Estimation of the Incidence Rate of Rare Diseases from Specialized Centers: Lessons Learned from a Study of Multicentric Castlemann’s Disease

Teltsch DY, Swain RS, Desrosiers M-P, Robinson Jr DW, Payne KA, Reynolds MW

**PRM227:** Considerations in the Application of Novel Statistical Methods for Crossover Adjustment in Trials of Cancer Treatments

Ishak J, Proskorovsky I, Korytowsky B, Sandin R

**SESSION II - Monday, May 20, 3:45 p.m. - 7:45 p.m.**

**PH130:** Cost Minimization Comparison of Darunavir + Ritonavir (DRV+RTV) to Lopinavir/Ritonavir (LPV/R) in HIV-1 Infected Treatment-Naive Women of Child Bearing Age (WOCBA)

Desai K, Möller J, Simpson KN, Baran RW, Van de Steen O, Dietz B, Gooch K

**PND10:** Predicting the Long-Term Clinical Effectiveness of Daclizumab in Relapsing-Remitting Multiple Sclerosis: A New Modeling Framework Using Discrete Event Simulation

Guo S, Hernandez L, Saint-Laurent Thibault C, Proskorovsky I, Philips GA

**PND17:** Study of Pseudobulbar Affect Symptoms in Veterans with Mild Traumatic Brain Injury

Fonda JR, McGlinchey RE, Milberg WP, Rudolph JL, Hunt PR, Reynolds MW, Yonan C

**SESSION III - Tuesday, May 21, 8:30 a.m. - 2:15 p.m.**

**PDB18:** Development of a Conceptual Disease Model to Assess Burden of Illness and Racial Differences: Case Study of Adult Females with Acne

Yeomans K, Kawata AK, Bassel M, Burk CT, Daniels SR, Wilcox TK

**PDB24:** Advantages of Bayesian Adaptive Trials for Comparative Effectiveness Research (CER): “Re-Adap’ting ALLHAT”

Broglia K, Ishak J, Mullins CD, Connor J, Luce BR, Davis B

**PDB64:** Development of a Conceptual Disease Model to Assess Burden of Illness and Racial Differences: Case Study of Adult Females with Acne

Yeomans K, Kawata AK, Bassel M, Burk CT, Daniels SR, Wilcox TK

**PDB82:** Assessment of Prevalence and Total Healthcare Costs of Associated Comorbidities among Commercially-Insured Type II Diabetics

Chen SY, Alas V, Wu Y, Greene M, Biskupiak J
PDB95: Evaluation of Polypharmacy in Patients with Type 2 Diabetes Mellitus and Its Association with Medication Adherence and Healthcare Costs
Chen SY, Alas V, Lee YC, Greene M, Oderda G

PDB101: Patient Characteristics, Antidiabetic Medication Use, and Glycemic Control in Diabetic Nursing Home Residents with Moderate to Severe Chronic Kidney Disease
Wu N, Greene M, Oderda G

PDB102: Association of Severe Hypoglycemic Events and Hospital Readmission with Treatment Non-concordance to Guidelines and Prescribing Information in Hospitalized Patients with Type 2 Diabetes and Stage 3-5 Chronic Kidney Disease
Chen SY, Alas V, Greene M

PDB103: Oral Antidiabetic Use among Nursing Home Residents with Diabetes and Moderate to Severe Chronic Kidney Disease
Wu N, Yu X, Greene M, Oderda G

PSS17: A Conceptual Framework of Functional Reading Independence in Geographic Atrophy
Tschosik EA, Bressler NM, Colman S, Dolan C, Leidy NK, Oestreicher N, Sunness JS, Varma R, Kimel M

PUK19: Content Validity of the Actionable Bladder Symptom Screening Tool (ABSST) in Non-Diabetic Females with Overactive Bladder (OAB) and Urgency Urinary Incontinence (UUI)
Nitti V, Dmochowski R, Chen WH, Signori M, Globe D, Wiklund I, Cardozo L

SESSION IV - Tuesday, May 21, 3:45 p.m. - 7:45 p.m.

PHS11: Economic Burden of Acute Urogenital Conditions among Type II Diabetes Patients and Non-Diabetics in the United States
Li Q, Wu N, Lee E, Sullivan PW

PHS20: Direct Medical Costs of Diabetes Complications in the United States
Alvarez P, Ward A, Chow W, Vo L, Martin S

PHS50: Association Between Comorbid Obesity with Health Status, Disability and Health-related Quality of Life in a Nationally Representative Type 2 Diabetes Mellitus Population
Chuang CC, Sy CH, Lee E, Sullivan PW

PHS598: Health Care Utilization and Costs Associated with Comorbid Obesity in Adults with Type 2 Diabetes Mellitus from a Nationally Representative US Population
Chuang CC, Chen SY, Lee E, Sullivan PW

PRS40: The EXACT in Idiopathic Pulmonary Fibrosis (IPF): Content Validity of an Existing Patient-Reported Outcome Measure for Use in a Rare Disease
Murray L, Vernon M, O’Quinn S, Martinez F, Parker JM, Leidy NK

PRS46: A Cross-sectional, Hybrid, Patient Survey and Chart Review Study Design to Assess Patterns of Care, Patient Reported Outcomes, and Quality of life in Patients with Chronic Obstructive Pulmonary Disease (COPD)
Desrosiers M-P, Payne KA, Boulanger L, Lordan N, Alas V, Zhang J, Massaro S

SESSION V - Wednesday, May 22, 8:30 a.m. - 2:45 p.m.

PCV38: Hospitalization and Mortality in Medicare Heart Failure Patients
Hunt PR, Veath BK, Tsintzos S, Burton ML, Mollenkopf SA

PCV42: Hospital Budget Impact of Readmission Penalties and Bundled Payments: Potential Impact of Coronary Stent Platforms
Kansal AR, Stern S, Cohen D, Reifsnider O, Meskan T, Allocco D, Hale BC

PCV49: Economic Analysis of Stent Platforms: Cost-Effectiveness of the Platinum Chromium Promus Element Compared to Cobalt Chromium Promus/Xience vs Everolimus-Eluting Stents
Hale BC, Stern S, Kansal AR, Allocco D, Dawkins K, Stone G

PCV68: Economic Comparison of Hemostatic Agents in Cardiac Surgery

Stop by Booth 3034 to speak with any of our presenters or to just learn more about our services!

Health Economics
Data Analytics ▪ Epidemiology
Outcomes Research ▪ Market Access

United BioSource Corporation